NCT04862780 2025-02-10(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCBlueprint Medicines CorporationPhase 1 Terminated177 enrolled
NCT05153408 2023-06-18(HARMONY) Study of BLU-701 in EGFR-mutant NSCLCBlueprint Medicines CorporationPhase 1 Terminated20 enrolled
NCT03255083 2022-01-19DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerDaiichi SankyoPhase 1 Terminated13 enrolled 19 charts